AAAAAA
Results:
1-9
|
Results: 9
Authors:
BAR FW
MEYER J
BOLAND J
BETRIU A
ARTMEYER B
CHARBONNIER B
MICHELS HR
TEBBE U
SPIECKER M
VERMEER F
VONFISENNE MJM
HOPKINS GR
BARTH H
Citation: Fw. Bar et al., BOLUS ADMINISTRATION OF SARUPLASE IN EUROPE (BASE), A PILOT-STUDY IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION, Journal of thrombosis and thrombolysis, 6(2), 1998, pp. 147-153
Authors:
TEBBE U
MICHELS R
ADGEY J
BOLAND J
CASPI A
CHARBONNIER B
WINDELER J
BARTH H
GROVES R
HOPKINS GR
FENNELL W
BETRIU A
RUDA M
MLCZOCH J
Citation: U. Tebbe et al., RANDOMIZED, DOUBLE-BLIND-STUDY COMPARING SARUPLASE WITH STREPTOKINASETHERAPY IN ACUTE MYOCARDIAL-INFARCTION - THE COMPASS EQUIVALENCE TRIAL, Journal of the American College of Cardiology, 31(3), 1998, pp. 487-493
Authors:
TEBBE U
GUNZLER WA
HOPKINS GR
GRYMBOWSKI T
BARTH H
Citation: U. Tebbe et al., THROMBOLYTIC THERAPY OF ACUTE MYOCARDIAL-INFARCTION WITH SARUPLASE, ASINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR (SCU-PA) FROM RECOMBINANT BACTERIA, Fibrinolysis & proteolysis, 11, 1997, pp. 45-54
Authors:
VANGRIENSVEN JMT
KOSTER RW
HOPKINS GR
BEIER H
GUNZLER WA
KROON R
SCHOEMAKER RC
COHEN AF
Citation: Jmt. Vangriensven et al., EFFECT OF CHANGES IN LIVER BLOOD-FLOW ON THE PHARMACOKINETICS OF SARUPLASE IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION, Thrombosis and haemostasis, 78(3), 1997, pp. 1015-1020
Authors:
VERMEER F
TEBBE U
HOPKINS GR
WINDELER J
MICHELS RH
BAR FW
BARTH H
Citation: F. Vermeer et al., MORTALITY AND STROKE RISK AFTER TREATMENT WITH SARUPLASE - OBSERVATIONS IN 2509 PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION, Circulation, 96(8), 1997, pp. 1847-1847
Authors:
MICHELS HR
HOFFMANN JJML
WINDELER J
HOPKINS GR
Citation: Hr. Michels et al., HEMOSTATIC CHANGES AFTER THROMBOLYTIC THERAPY WITH SARUPLASE (UNGLYCOSYLATED SINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR) AND UROKINASE (2-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR), Blood coagulation & fibrinolysis, 7(8), 1996, pp. 766-771
Authors:
VERMEER F
HOPKINS GR
WINDELER J
TEBBE U
MICHELS RH
BAR FW
BARTH H
Citation: F. Vermeer et al., EFFICACY AND SAFETY DATA OF 4317 PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION TREATED WITHIN 6 HOURS AFTER ONSET WITH SARUPLASE, Circulation, 94(8), 1996, pp. 4356-4356
Authors:
VERMEER F
BAR FW
WINDELER J
HOPKINS GR
BARTH H
Citation: F. Vermeer et al., SARUPLASE - EFFICACY AND SAFETY DATA OF 2570 PATIENTS, Journal of the American College of Cardiology, 1994, pp. 10000345-10000345
Authors:
KOSTER RW
COHEN AF
HOPKINS GR
BEIER H
GUNZLER WA
VANDERWOUW PA
Citation: Rw. Koster et al., PHARMACOKINETICS AND PHARMACODYNAMICS OF SARUPLASE, AN UNGLYCOSYLATEDSINGLE-CHAIN UROKINASE-TYPE PLASMINOGEN-ACTIVATOR, IN PATIENTS WITH ACUTE MYOCARDIAL-INFARCTION, Thrombosis and haemostasis, 72(5), 1994, pp. 740-744
Risultati:
1-9
|